![]() |
市場調查報告書
商品編碼
1368689
單細胞組學市場- 按產品類型(基因組學、轉錄組學、蛋白質組學、代謝組學)、應用(腫瘤學、細胞生物學、神經學、免疫學)、最終用戶(製藥和生物技術公司、醫院實驗室)、全球預測(2023 - 2032 年) )Single-cell Omics Market - By Product Type (Genomics, Transcriptomics, Proteomics, Metabolomics), Application (Oncology, Cell Biology, Neurology, Immunology), End-user (Pharma & Biotech Companies, Hospital Laboratories), Global Forecast (2023 - 2032) |
由於個人化治療的需求不斷成長,單細胞組學市場規模預計從 2023 年到 2032 年年複合成長率將超過 20%。隨著癌症和自體免疫疾病等複雜疾病的盛行率不斷上升,需要量身定做的治療方法。根據一項針對 2,200 萬人的最新研究,在英國,近 10% 的人口患有 19 種自體免疫疾病。
此外,生物技術和基因組學研究的快速進步,加上對理解細胞異質性的關注,正在推動單細胞組學技術在各種研究和臨床應用中的採用。
整個單細胞組學市場根據產品類型、應用、最終用戶和地區進行分類。
由於強調揭示單一細胞內複雜的蛋白質動態,單細胞蛋白質體學領域預計 2023 年至 2032 年的年複合成長率將達到 20.6%。蛋白質體學可以深入了解細胞功能和蛋白質相互作用。新興技術正在徹底改變研究人員和臨床醫生在單細胞層級研究蛋白質表現和翻譯後修飾的方式,從而促進疾病研究和藥物開發的突破性見解。
隨著單細胞組學在許多研究領域展現其變革潛力,細胞生物學領域在 2023 年至 2032 年期間的年複合成長率將達到 20.5%。從破解腫瘤異質性的複雜性到揭示免疫細胞多樣性的複雜性,單細胞組學技術正在使細胞生物學研究取得前所未有的進展。透過提供對細胞行為的細緻入微的理解,這些技術正在增強新治療標靶的識別並促進精確治療策略的發展,從而促進再生醫學、免疫療法和發育生物學領域的突破。
由於該地區生物技術研究的大幅成長,預計亞太地區單細胞組學產業規模從 2023 年到 2032 年的年複合成長率將達到 20.7%。中國、日本和韓國等國家越來越關注精準醫療計畫。研發投資的快速成長,加上慢性病盛行率的上升,推動了不同臨床和研究環境對先進單細胞組學解決方案的需求,凸顯了該地區在塑造精準醫療未來方面的關鍵作用。
The single-cell omics market size to expected record over 20% CAGR from 2023 to 2032, owing to the escalating demand for personalized therapeutics. With the rising prevalence of complex diseases such as cancer and autoimmune disorders, there is a need for tailored treatments. According to a latest study based on 22 million people, in UK, nearly 10% of the population is suffering from a list of 19 autoimmune disorders.
Furthermore, the rapid advancements in biotechnology and genomics research, coupled with the focus on understanding cellular heterogeneity, are driving the adoption of single cell omics technologies across diverse research and clinical applications.
The overall single-cell omics market is classified as per product type, application, end-user, and region.
The single-cell proteomics segment is anticipated to record 20.6% CAGR from 2023 to 2032 owing to the emphasis on unraveling intricate protein dynamics within individual cells. The proteomics enable in-depth understanding of cellular functions and protein interactions. Emerging technologies are revolutionizing the way researchers and clinicians approach the study of protein expression and post-translational modifications at the single-cell level, thereby facilitating groundbreaking insights for disease research and drug development.
The cell biology segment will observe 20.5% CAGR during 2023-2032 as single cell omics is demonstrating its transformative potential across a myriad of research domains. From deciphering the complexities of tumor heterogeneity to unraveling the intricacies of immune cell diversity, single cell omics technologies are enabling unprecedented advancements in cell biology research. By providing a nuanced understanding of cellular behavior, these technologies are enhancing the identification of novel therapeutic targets and fostering the development of precise treatment strategies, thus fostering breakthroughs in the fields of regenerative medicine, immunotherapy, and developmental biology.
Asia Pacific single cell omics industry size is predicted to witness 20.7% CAGR from 2023 to 2032 owing to the significant upsurge in biotechnology research across the region. There is mounting focus on precision medicine initiatives in countries such as China, Japan, and South Korea. The burgeoning investments in R&D, coupled with the rising prevalence of chronic diseases, are propelling the demand for advanced single cell omics solutions across diverse clinical and research settings, thereby underscoring the region's pivotal role in shaping the future of precision medicine.